Is the Role of Hepcidin and Erythroferrone in the Pathogenesis of Beta Thalassemia the Key to Developing Novel Treatment Strategies?

Thalassemia is a disease of erythrocytes that varies largely on its genetic composition and associated clinical presentation. Though some patients may remain asymptomatic, those with complicated course experience severe anemia early in childhood, carrying into adulthood requiring recurrent blood transfusions as pillar symptom management. Due to the consequences ineffective erythropoiesis frequent transfusions, beta thalassemia be subsequently susceptible hemochromatosis. In light established role hepcidin erythroferrone pathogenesis thalassemia, this review aims discuss current trials studies field while presenting implications HAMP gene polymorphisms novel treatments. Research suggested incorporating serum testing part routine workups for they could predictive tool iron accumulation. Furthermore, ameliorating low high appeared crucial treating complications due overload. Currently, hepcidin-like compounds, such minihepcidins, LJPC-401, PTG-300, VIT-2763, agents promote production by inhibiting TMPRSS6 expression or erythroferrone, were shown effective restoring homeostasis preliminary studies. Moreover, natural bioactives astragalus polysaccharide icariin have been recently recognized inductors.